30 related articles for article (PubMed ID: 1868270)
1. Parathyroid hormone analogues in the treatment of osteoporosis.
Kraenzlin ME; Meier C
Nat Rev Endocrinol; 2011 Jul; 7(11):647-56. PubMed ID: 21750510
[TBL] [Abstract][Full Text] [Related]
2. Effects of PTH treatment on tibial bone of ovariectomized rats assessed by in vivo micro-CT.
Brouwers JE; van Rietbergen B; Huiskes R; Ito K
Osteoporos Int; 2009 Nov; 20(11):1823-35. PubMed ID: 19262974
[TBL] [Abstract][Full Text] [Related]
3. Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size.
Burr DB
Curr Osteoporos Rep; 2005 Mar; 3(1):19-24. PubMed ID: 16036097
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of bone loss and gain in untreated and treated osteoporosis.
Compston J
Endocrine; 2002 Feb; 17(1):21-7. PubMed ID: 12014699
[No Abstract] [Full Text] [Related]
5. Osteoporosis in men. New insights into aetiology, pathogenesis, prevention and management.
Ebeling PR
Drugs Aging; 1998 Dec; 13(6):421-34. PubMed ID: 9883398
[TBL] [Abstract][Full Text] [Related]
6. Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol.
Shen V; Dempster DW; Birchman R; Xu R; Lindsay R
J Clin Invest; 1993 Jun; 91(6):2479-87. PubMed ID: 8514860
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis.
Hasling C; Charles P; Jensen FT; Mosekilde L
Osteoporos Int; 1994 Jul; 4(4):191-203. PubMed ID: 7949749
[TBL] [Abstract][Full Text] [Related]
8. Therapy of male osteoporosis with parathyroid hormone.
Bilezikian JP; Kurland ES
Calcif Tissue Int; 2001 Oct; 69(4):248-51. PubMed ID: 11730261
[TBL] [Abstract][Full Text] [Related]
9. Osteoporosis: how should it be treated?
Odvina CV
J Investig Med; 2006 Apr; 54(3):114-22. PubMed ID: 16948394
[TBL] [Abstract][Full Text] [Related]
10. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients.
Hodsman AB; Steer BM; Fraher LJ; Drost DJ
Bone Miner; 1991 Jul; 14(1):67-83. PubMed ID: 1868270
[TBL] [Abstract][Full Text] [Related]
11. Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients.
Hodsman AB; Fraher LJ
Bone Miner; 1990 May; 9(2):137-52. PubMed ID: 2161692
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
Hodsman AB; Fraher LJ; Ostbye T; Adachi JD; Steer BM
J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043
[TBL] [Abstract][Full Text] [Related]
14. Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis.
Hodsman AB; Kisiel M; Adachi JD; Fraher LJ; Watson PH
Bone; 2000 Aug; 27(2):311-8. PubMed ID: 10913928
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
